Harmony Biosciences Holdings (HRMY) Change in Accured Expenses (2019 - 2025)
Harmony Biosciences Holdings (HRMY) has disclosed Change in Accured Expenses for 7 consecutive years, with $52.5 million as the latest value for Q4 2025.
- Quarterly Change in Accured Expenses rose 317.11% to $52.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $68.0 million through Dec 2025, up 476.27% year-over-year, with the annual reading at $68.0 million for FY2025, 476.27% up from the prior year.
- Change in Accured Expenses hit $52.5 million in Q4 2025 for Harmony Biosciences Holdings, up from $28.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $52.5 million in Q4 2025 to a low of -$22.8 million in Q4 2022.
- Historically, Change in Accured Expenses has averaged $8.2 million across 5 years, with a median of $5.9 million in 2021.
- Biggest five-year swings in Change in Accured Expenses: surged 535.86% in 2022 and later crashed 637.48% in 2024.
- Year by year, Change in Accured Expenses stood at $8.7 million in 2021, then plummeted by 360.98% to -$22.8 million in 2022, then soared by 235.23% to $30.8 million in 2023, then tumbled by 59.13% to $12.6 million in 2024, then surged by 317.11% to $52.5 million in 2025.
- Business Quant data shows Change in Accured Expenses for HRMY at $52.5 million in Q4 2025, $28.0 million in Q3 2025, and -$7.0 million in Q2 2025.